Articles tagged with Heart Failure
A study found that carvedilol did not significantly improve heart failure outcomes in children and adolescents. The researchers evaluated the effects of carvedilol on 161 children and adolescents with heart failure and found no statistically significant difference between treatment groups.
A new analysis of four studies found that long-term use of Avandia increased the risk of heart attack by 42% and doubled the risk of heart failure. The study, published in JAMA, suggests that the drug may cause over 4,000 excess heart attacks and 9,000 excess cases of heart failure per year.
A meta-analysis of pioglitazone treatment found a significant reduction in heart attack, stroke, and death rates among type 2 diabetes patients, with no significant increase in cardiovascular death. However, the treatment also increased the risk for serious heart failure.
Researchers at the University of Texas M. D. Anderson Cancer Center found that congestive heart failure is rare among leukemia patients taking imatinib. Only 22 out of 1,276 patients developed symptoms that could be caused by heart failure, and most had underlying medical conditions that also contributed to their condition.
A new study suggests that PPAR-gamma agonists, used to treat diabetes, may cause heart failure due to fat accumulation and cell dysfunction. Increased activity of the receptor leads to glucolipotoxicity, a condition characterized by deterioration in heart function.
A new generation of implanted heart-assisting pump has shown excellent survival rates and significant improvements in patient quality of life. The device, called the HeartMate II, helped 75% of patients stay alive for at least six months or until a donor heart became available.
Researchers produced human cardiomyocytes from hESCs using a sequential, directed differentiation protocol that did not rely on serum or feeder cells. Echocardiography showed attenuation of left-ventricular end-diastolic and end-systolic diameters in animals receiving cardiomyocytes compared to control groups.
A study published in Critical Care suggests that large burns can lead to cardiac problems, inflammatory responses, and hypermetabolic states. Effective treatments may focus on addressing these multiple aspects, including inflammation and organ function.
Researchers found that impaired energy production in heart muscle may underlie heart failure in some hypertensive patients. A protein called estrogen-related receptor alpha (ERR alpha) helps the heart keep up with energy-draining conditions like high blood pressure.
A study published in JCI reveals that Gq/G11-mediated signaling plays a crucial role in transmitting TSH-induced signals, regulating thyroid gland function. Mice lacking the alpha-subunits of both Gq and G11 exhibited reduced thyroid gland function and symptoms similar to hypothyroidism.
Researchers discovered that blood levels of protein ST2 indicate the presence of heart failure and predict the risk of death, even among patients without heart failure. A combination of ST2 with other biomarkers provides the most accurate prediction for all study participants.
Researchers investigate causes and treatment options for pediatric heart failure, including gene regulation, cell regeneration, and surgical interventions. The grant aims to improve treatments and reduce the need for heart transplants in children.
A class of diabetes drugs increases the risk of heart failure in patients with type 2 diabetes, according to a new analysis of over 78,000 patients. The risk is estimated to be up to 100% higher in patients taking thiazolinediones, and may be triggered by fluid retention caused by the drugs.
A national initiative designed to improve heart-failure patient care in hospitals resulted in significant gains, including increased adherence to key quality-of-care performance measures and reduced hospital stays. The initiative also led to favorable trends for in-hospital and post-discharge mortality rates.
Researchers at the University of Pittsburgh School of Medicine are developing a novel approach to treat both congestive heart failure and major depression. The study aims to compare the impact of blended care management programs with traditional programs on various outcomes.
A University of Alberta study found that rural Albertans' strong work ethic and sense of place can influence their decision not to seek medical help for congestive heart failure. This can lead to delayed diagnosis and treatment, with patients often waiting days or even weeks for symptoms to subside.
Research found that aerobic exercise, such as walking or bicycling, significantly improved ejection fraction and reduced heart size in patients with stable heart failure. In contrast, combining aerobic exercise with strength training showed no similar benefits.
A five-year study found no significant increase in congestive heart failure among women treated with Herceptin and chemotherapy. The research team developed a prediction model to assess individual cardiac risk factors and personalize treatment.
A simple exercise test can help predict mortality risk in patients with heart failure and inform personalized treatment plans. The test measures lung efficiency and has been shown to predict future hospitalizations in systolic heart failure patients.
UPMC has started a study using the VentrAssist LVAD, a mechanical blood pump to assist the heart in pumping blood around the body. The study aims to enroll 30 patients for a multi-center feasibility trial to explore its safety and effectiveness as a bridge to transplantation.
A new study shows Pycnogenol supplementation can prevent damage to the heart caused by high blood pressure and hypertension. The natural pine bark extract enhanced collagen connective tissues in cardiac tissue, resulting in stronger cardiac chambers.
A study of 314 low-income Indiana residents with heart failure found that pharmacist-led patient-centered care resulted in patients taking their medications 16% more consistently. This approach also reduced emergency room visits and hospitalizations by 19%, saving the healthcare system $14 in costs for every dollar spent.
A novel catheter technique successfully patched ventricular septal defects (VSDs) in nearly all patients, restoring normal blood circulation and relieving fluid backup in the lungs. After recovery, patients regained enough strength to safely undergo surgical repair or return to active lives.
Catheter-based aortic valve replacement using the CoreValve system improves aortic valve size and reduces heart failure severity in elderly patients. The procedure has been successfully performed on 17 high-risk patients, with all surviving the operation.
Implanted pumps improved heart function in many patients awaiting a heart transplant, allowing them to leave the hospital without a pump and without a new heart. The devices also showed progressive improvement in exercise capacity and reduced signs of heart damage.
A simple blood test taken at hospital admission can predict in-hospital mortality risk for heart failure patients, says UCLA researcher. Higher BNP levels are associated with higher mortality rates and other clinical outcomes such as mechanical ventilation and longer hospital stays.
A new study by UCLA researchers found significant changes in treatment patterns and quality-of-care indicators that paralleled improvements in clinical outcomes and mortality rates for heart failure patients. The study reported a 29% reduction in in-hospital mortality and a 36% reduction in the need for mechanical ventilation.
Researchers found a significant decline in death rates and heart failure among patients with severe heart attacks, with reductions of 4.5% and 11%, respectively. The study also showed improvements in stroke and further heart attack risk.
Researchers found that statin drugs can lower resting sympathetic nervous system activity, a factor associated with increased mortality in heart failure patients. This decrease in activity is linked to improved health outcomes and reduced risk of heart failure and sudden cardiac death.
A study published in JAMA Network found that levosimendan did not improve survival rates for patients with decompensated heart failure compared to dobutamine. The researchers analyzed data from 1,327 patients who received either intravenous levosimendan or dobutamine and found no significant difference in long-term survival outcomes.
Recent changes in treatment guidelines for acute coronary syndromes have been associated with reductions in heart failure, stroke, and death rates. The use of pharmacological medications increased over time, while primary PCI rates rose by 37 percentage points.
Researchers provide new insights into how a key protein used to fight viruses works, raising hopes for improved treatments against viral infection. Additionally, heart stem cells are shown to be unaffected by acute heart failure, making them available for cardiac recovery. A chemical called thioredoxin also helps prevent loss of neuron...
A new nuclear medicine technique using annexin A5 imaging may help identify individuals at risk of developing heart failure by detecting programmed cell loss in the heart muscle. This could lead to earlier intervention and improved treatment options, as cell death is a key factor in worsening left ventricular events.
Researchers monitored nearly 7,000 participants of different ethnic backgrounds, revealing that African Americans developed heart failure at significantly higher rates due to diabetes and hypertension. However, when statistical techniques excluded these risk factors, racial differences in heart failure rates disappeared.
According to two studies, disease management programs designed with repetitive education and close monitoring can reduce hospital visits and increase heart failure patients' chances of long-term survival. The REMADHE study found that patients who received a nurse-based program spent an average of nine fewer days in the hospital.
The EVEREST trial showed that tolvaptan improved signs and symptoms of acutely decompensated heart failure, with significant reductions in body weight and improvements in dyspnea. Long-term use did not differ from placebo on survival endpoints, but tolvaptan may be a potential therapy for patients with heart failure.
Researchers at Thomas Jefferson University have found that outpatient medication usage is not associated with anemia in patients admitted with decompensated heart failure. Additionally, the team discovered that beta blocker dose adjustment upon hospitalization for acute decompensated heart failure can increase length of stay, and Fibul...
A randomized trial found that Crataegus Extract WS1442 safely prolongs the lives of congestive heart failure patients, reducing cardiac-related deaths by 20%. The study involved 2,681 patients and confirmed the safety of the compound, which is currently approved for use in some European countries.
A new implantable device has shown to effectively maintain heart function in transplant-listed patients, improving survival rates and quality of life. The study also explores the benefits of diuretic therapies in supporting left ventricular function, with promising results.
A recent study by Johns Hopkins Medicine found that African Americans have weaker muscle contraction in three main regions of the heart, increasing their risk of heart failure. In contrast, Chinese Americans' hearts had a stronger squeezing function and contracted more quickly than other ethnic groups.
A new noninvasive test may identify patients with stage II and III nonischemic cardiomyopathy who are likely to benefit from an ICD. The test, called abnormal T-Wave Alternans (TWA), shows that patients with a normal test have a very good prognosis and are unlikely to benefit from the device.
A new study found that serial outpatient administration of nesiritide did not significantly improve outcomes in patients with advanced heart failure. The trial, FUSION II, tested the safety and efficacy of this treatment approach and showed no evidence of renal harm or excess mortality.
The EVEREST trial shows that oral tolvaptan improves patient-assessed global clinical status, body weight, and reduces dyspnea in hospitalized heart failure patients, while also measuring long-term effects on mortality and hospitalization rates.
A study found that tolvaptan improves symptoms such as congestion and breathing difficulty, but has no effect on long-term mortality or re-hospitalization rates. The medication also showed promise in reducing fluid accumulation and improving sodium levels in patients with hyponatremia.
A survey found significant variation in the use of captopril, an adult heart drug, in children with congenital heart failure across the UK. The discrepancies may lead to ineffective treatment and increased risk for children.
Increased expression of an accessory subunit of L-type calcium channels is linked to altered channel behavior in human heart failure. Researchers have identified a causal role for this protein overexpression in the development of cardiac dysfunction.
Eating whole-grain breakfast cereals seven or more times per week was linked to a lower risk of heart failure in an analysis of the Physicians' Health Study. The study found that those who ate such cereals had a 28% lower risk of developing heart failure.
A new study shows that Transcendental meditation significantly improves heart function and quality of life for African Americans with congestive heart failure. The technique was found to reduce symptoms such as depression and rehospitalizations, leading to improved survival rates.
A study by Duke University Medical Center researchers found that depression is independently associated with worse outcomes in heart failure patients. Symptoms of depression were common in this population and depressed patients were over 50% more likely to die or be hospitalized for their heart condition than non-depressed patients.
Researchers at the University of Pennsylvania School of Medicine discovered that an enzyme important in fetal heart-cell development regulates cardiac hypertrophy, a key step in congestive heart failure. The study found that inhibiting this enzyme can prevent the onset of cardiac hypertrophy and heart failure.
Researchers at Thomas Jefferson University have discovered a new strategy against heart failure by targeting the adrenal gland. By blocking GRK2, an enzyme that regulates fight or flight hormones, they were able to reduce hormone production and improve heart function.
A new study reveals that mice lacking a critical gene develop postpartum cardiomyopathy, a condition where prolactin-blocking drug bromocriptine reverses symptoms. The research found increased levels of cathepsin D, an enzyme that damages heart muscle, in PPCM patients.
A study published in Cell Metabolism reveals that the MAT1 gene plays a crucial role in regulating energy production in heart cells. Researchers found that infant mice lacking MAT1 developed catastrophic heart failure, highlighting the importance of this gene in maintaining cardiac function.
Researchers from Indiana University found that active patient involvement during treatment of chronic heart failure, coupled with collaboration between healthcare teams, significantly improves quality of care. Lifestyle changes such as exercise, reducing salt intake, and managing stress are also crucial for longer survival rates.
A large international study involving 83 sites will test 3,000 patients to evaluate the impact of exercise training on death and hospitalization in heart failure patients. The trial, called HF-ACTION, is the largest randomized clinical trial of exercise training ever performed.
A study of over 100,000 acute heart failure patient episodes found that obese patients had a substantially lower in-hospital mortality rate compared to lean patients. The findings suggest that nutritional/metabolic support may have therapeutic benefit in specific patients hospitalized with heart failure.
A genetic mutation in a single amino acid change in the beta1-adrenergic receptor affects its response to certain beta blockers. The Arg389 variant of the receptor is more sensitive to carvedilol, leading to reduced cAMP signaling and potentially poorer treatment outcomes for black patients.
A study found that four out of five hospital performance measures for heart failure were not linked to improved patient outcomes. The measures, developed by the American College of Cardiology and American Heart Association, include discharge instructions and evaluation of left ventricular systolic function.
Researchers found that existing quality-of-care indicators for heart failure patients may not accurately predict mortality rates. A new beta-blocker measure was associated with improved patient outcomes and could potentially save an additional 19,000 lives per year.
Researchers at the University of Illinois Chicago have developed a new formula to determine the initial dose of digoxin for patients with congestive heart failure. The formula uses blood digoxin levels, kidney function, and ideal body weight to provide more accurate dosing recommendations, reducing the risk of overdose or underdose.